News and Events

Leadership Q&A: NIH to bolster RECOVER Long COVID research efforts

Gary Gibbons, M.D., Walter Koroshetz, M.D., and Jeanne Marrazzo, M.D., M.P.H. of the NIH answer questions about investing an additional $515 million in RECOVER's Long COVID research efforts.

NIH to bolster RECOVER Long COVID research efforts through infusion of $515 million

This additional funding will build on and continue RECOVER's work to improve our understanding of and ability to diagnose, prevent, and treat Long COVID.

RECOVER-NEURO enrolls first participant in trial

RECOVER-NEURO will enroll 315 people and test several different treatments for Long COVID patients who have difficulty focusing, thinking clearly, and remembering things.

NIH launches long COVID clinical trials through RECOVER Initiative, opening enrollment

Initially, RECOVER will test at least four potential treatments for Long COVID, with test of seven more treatments expected in the coming months.

RECOVER-VITAL enrolls first participant in trial

RECOVER-VITAL will enroll 900 people over the next six months and seek to understand whether taking Paxlovid, an antiviral drug, can improve Long COVID symptoms caused by viral persistence.

NIH Director’s blog: What Clinical Research Comes Next for Helping People with Long COVID

Three leaders at the NIH explain how patient experiences have guided and will continue to guide RECOVER's efforts to understand, diagnose, prevent, and treat Long COVID.

RECOVER program takes first steps in advancing toward clinical trials to better understand Long COVID

RECOVER will launch several clinical trials to find treatments for five of the most burdensome symptom clusters identified by people suffering from Long COVID.

Duke Selected as RECOVER Clinical Trials Data Coordinating Center

The Duke Clinical Research Institute (DCRI) will oversee RECOVER’s efforts to find safe and effective treatments for Long COVID symptoms.